BET-Inhibitor

DRUG2 trials

Sponsors

Celgene Corp., Bristol-Myers Squibb Services Unlimited Company

Conditions

DIPSS-Intermediate or High Risk MyelofibrosisRelapsed or Refractory Multiple Myeloma (RRMM)

Phase 1

A Phase 1b/2 Study of BMS-986158 Monotherapy and in Combination with Either Ruxolitinib or Fedratinib in Participants with DIPSS-Intermediate or High Risk Myelofibrosis

Active, not recruitingCTIS2023-509635-89-00

Bristol-Myers Squibb Services Unlimited CompanyDIPSS-Intermediate or High Risk Myelofibrosis

Start: 2021-06-01Target: 132Updated: 2026-01-12

An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants with Relapsed or Refractory Multiple Myeloma

RecruitingCTIS2023-509384-25-00

Celgene Corp.Relapsed or Refractory Multiple Myeloma (RRMM)

Start: 2022-12-30Target: 56Updated: 2025-10-10